Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
| Autor: | Chowdhury, S., Bjartell, A., Agarwal, N., Chung, B.H., Given, R.W., Pereira de Santana Gomes, A.J., Merseburger, A.S., Özgüroğlu, M., Juárez Soto, Á., Uemura, H., Ye, D., Brookman-May, S.D., Londhe, A., Bhaumik, A., Mundle, S.D., Larsen, J.S., McCarthy, S.A., Chi, K.N. |
|---|---|
| Zdroj: | In Annals of Oncology May 2023 34(5):477-485 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|